NCT07476677 2026-03-17
ANDARP
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
Clinical Trials
28 trialsNCT06173362 2026-03-13
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
University of California, Davis
Phase 2 Recruiting
NCT05526248 2026-03-11
ARAMON
Bayer
Phase 2 Completed
NCT06463457 2026-03-09
Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT07450599 2026-03-05
CHINANEO
Bayer
Phase 2 Not yet recruiting
NCT05059236 2026-02-09
ARASEC
Bayer
Phase 2 Active not recruiting
NCT06734130 2026-01-21
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT06378866 2025-12-26
DIVINE
Mayo Clinic
Phase 2 Recruiting
NCT04025372 2025-12-15
INTREPId (INTermediate Risk Erection PreservatIon Trial)
Brigham and Women's Hospital
Phase 2 Active not recruiting
NCT07282197 2025-12-15
Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019
Peking University First Hospital
Phase 2 Not yet recruiting
NCT04335682 2025-11-04
ARACOG
Alliance Foundation Trials, LLC.
Phase 2 Active not recruiting
NCT02972060 2025-09-19
ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Active not recruiting
NCT03385655 2025-08-21
Prostate Cancer Biomarker Enrichment and Treatment Selection
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT04319783 2025-08-21
DECREASE
Trans Tasman Radiation Oncology Group
Phase 2 Active not recruiting
NCT06401980 2025-08-14
Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Swiss Cancer Institute
Phase 2 Recruiting
NCT05171387 2025-06-22
Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer
Bayer
Phase 2 Completed
NCT07027124 2025-06-18
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Not yet recruiting
NCT04925648 2025-05-15
PICASSO
St Vincent's Hospital, Sydney
Phase 2 Recruiting
NCT04070209 2024-12-04
Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)
Sir Mortimer B. Davis - Jewish General Hospital
Phase 2 Recruiting
NCT06575257 2024-08-28
Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer
Xijing Hospital
Phase 2 Recruiting
NCT05762536 2024-06-27
DAROTAXEL
Erasmus Medical Center
Phase 2 Recruiting
NCT02933801 2024-03-13
ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.
Swiss Cancer Institute
Phase 2 Terminated
NCT04641078 2024-02-28
DART
University Hospital, Ghent
Phase 2 Unknown
NCT04176081 2024-01-24
SChLAP/IDC
University Health Network, Toronto
Phase 2 Not yet recruiting
NCT05900973 2023-08-07
A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer
D'Or Institute for Research and Education
Phase 2 Unknown
NCT04157088 2023-08-04
DaroAcT
Bayer
Phase 2 Terminated
NCT05249712 2023-01-03
Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Unknown
NCT01429064 2017-02-20
Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001
Orion Corporation, Orion Pharma
Phase 2 Completed